Lansoprazole
B-Cell Chronic Lymphocytic Leukemia
King's College Hospital NHS TrustSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
67 Active assets in the B-Cell Chronic Lymphocytic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Humax-Cd20 Emory University | Phase 4 | BBB |
Acalabrutinib Zulfa Omer | Phase 4 | BBB |
Fludarabine Ohio State University Comprehensive Cancer Center | Phase 4 | BBB |
Rituximab Zulfa Omer | Phase 4 | BBB |
Cyclophosphamide Ohio State University Comprehensive Cancer Center | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Lansoprazole is also rated in:
metabolic dysfunction-associated steatotic liver diseaseDormant
BB
Indicative · Phase 4
65 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →